Strategies to identify the Lynch syndrome among patients with colorectal cancer

Annals of Internal Medicine

Volumn 155, Issue 2, 2011, Pages 69-79

  Ladabaum, Uri ^a   Wang, Grace ^b   Terdiman, Jonathan ^b   Blanco, Amie ^c   Kuppermann, Miriam ^d   Richard Boland, C ^e   Ford, James ^a   Elkin, Elena ^f   Phillips, Kathryn A ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE;

ADULT; AGE; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CANCER TEST; CLINICAL EFFECTIVENESS; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; FEMALE; GENDER; GENETIC SCREENING; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HEREDITY; HUMAN; IMMUNOHISTOCHEMISTRY; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; SENSITIVITY ANALYSIS;

EID: 79960604164     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-155-2-201107190-00002     Document Type: Article

References (103)

1. Aarnio M, Sankila R, Pukkala E, Salovaara R, Aaltonen LA, de la Chapelle A, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer. 1999;81:214-218.
2. Dunlop MG, Farrington SM, Carothers AD, Wyllie AH, Sharp L, Burn J, et al. Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet. 1997;6:105-110.
3. Choi YH, Cotterchio M, McKeown-Eyssen G, Neerav M, Bapat B, Boyd K, et al. Penetrance of colorectal cancer among MLH1/MSH2 carriers participating in the colorectal cancer familial registry in Ontario. Hered Cancer Clin Pract. 2009;7:14.
4. Hendriks YM, de Jong AE, Morreau H, Tops CM, Vasen HF, Wijnen JT, et al. Diagnostic approach and management of Lynch syndrome (hereditary non-polyposis colorectal carcinoma): a guide for clinicians. CA Cancer J Clin. 2006; 56:213-225.
5. Lynch HT, Boland CR, Gong G, Shaw TG, Lynch PM, Fodde R, et al. Phenotypic and genotypic heterogeneity in the Lynch syndrome: diagnostic, surveillance and management implications. Eur J Hum Genet. 2006;14:390-402.
6. Gruber SB. New developments in Lynch syndrome (hereditary nonpolyposis colorectal cancer) and mismatch repair gene testing. Gastroenterology. 2006;130: 577-587.
7. Järvinen HJ, Aarnio M, Mustonen H, Aktan-Collan K, Aaltonen LA, Pel-tomäki P, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology. 2000; 118:829-834.
8. Schmeler KM, Lynch HT, Chen LM, Munsell MF, Soliman PT, Clark MB, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med. 2006;354:261-269.
9. Lindor NM, Petersen GM, Hadley DW, Kinney AY, Miesfeldt S, Lu KH, et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA. 2006;296:1507-1517.
10. Vasen HF, Abdirahman M, Brohet R, Langers AM, Kleibeuker JH, van Kouwen M, et al. One to 2-year surveillance intervals reduce risk of colorectal cancer in families with Lynch syndrome. Gastroenterology. 2010;138:2300-6.
11. Järvinen HJ, Renkonen-Sinisalo L, Aktán-Collán K, Peltomäki P, Aaltonen LA, Mecklin JP. Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. J Clin Oncol. 2009;27:4793-4797.
12. Stupart DA, Goldberg PA, Algar U, Ramesar R. Surveillance colonoscopy improves survival in a cohort of subjects with a single mismatch repair gene mutation. Colorectal Dis. 2009;11:126-130.
13. Aaltonen LA, Salovaara R, Kristo P, Canzian F, Hemminki A, Peltomäki P, et al. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med. 1998;338:1481-1487.
14. Barnetson RA, Tenesa A, Farrington SM, Nicholl ID, Cetnarskyj R, Por-teous ME, et al. Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N Engl J Med. 2006;354:2751-2763.
15. Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med. 2005;352:1851-1860.
16. Piňol V, Castells A, Andreu M, Castellví-Bel S, Alenda C, Llor X, et al; Gastrointestinal Oncology Group of the Spanish Gastroenterological Association. Accuracy of revised Bethesda guidelines, microsatellite instability, and im-munohistochemistry for the identification of patients with hereditary nonpolypo-sis colorectal cancer. JAMA. 2005;293:1986-1994.
17. Salovaara R, Loukola A, Kristo P, Kääriäinen H, Ahtola H, Eskelinen M, et al. Population-based molecular detection of hereditary nonpolyposis colorectal cancer. J Clin Oncol. 2000;18:2193-2200.
18. Samowitz WS, Curtin K, Lin HH, Robertson MA, Schaffer D, Nichols M, et al. The colon cancer burden of genetically defined hereditary nonpolyposis colon cancer. Gastroenterology. 2001;121:830-838.
19. Terdiman JP. It is time to get serious about diagnosing Lynch syndrome (hereditary nonpolyposis colorectal cancer with defective DNA mismatch repair) in the general population [Editorial]. Gastroenterology. 2005;129:741-744.
20. Surveillance, Epidemiology, and End Results (SEER) Program. SEER Stat Fact Sheets: Colon and Rectum. Bethesda, MD: National Cancer Institute; 2010. Accessed at http://seer.cancer.gov/statfacts/html/colorect.html on 23 May 2011.
21. Ramsey SD, Clarke L, Etzioni R, Higashi M, Berry K, Urban N. Cost-effectiveness of microsatellite instability screening as a method for detecting hereditary nonpolyposis colorectal cancer. Ann Intern Med. 2001;135:577-588.
22. Ramsey SD, Burke W, Clarke L. An economic viewpoint on alternative strategies for identifying persons with hereditary nonpolyposis colorectal cancer. Genet Med. 2003;5:353-363.
23. Mvundura M, Grosse SD, Hampel H, Palomaki GE. The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. Genet Med. 2010;12:93-104.
24. Reyes CM, Allen BA, Terdiman JP, Wilson LS. Comparison of selection strategies for genetic testing of patients with hereditary nonpolyposis colorectal carcinoma: effectiveness and cost-effectiveness. Cancer. 2002;95:1848-1856.
25. Kievit W, de Bruin JH, Adang EM, Severens JL, Kleibeuker JH, Sijmons RH, et al. Cost effectiveness of a new strategy to identify HNPCC patients. Gut. 2005;54:97-102.
26. Bonis PA, Trikalinos TA, Chung M, Chew P, Ip S, DeVine DA, et al. Hereditary Nonpolyposis Colorectal Cancer: Diagnostic Strategies and Their Implications. Evidence report/technology assessment no. 150. Rockville, MD: Agency for Healthcare Research and Quality; 2007.
27. Jascur T, Boland CR. Structure and function of the components of the human DNA mismatch repair system. Int J Cancer. 2006;119:2030-2035.
28. Lindor NM, Rabe K, Petersen GM, Haile R, Casey G, Baron J, et al. Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type 10. JAMA. 2005;293:1979-85.
29. Hampel H, Stephens JA, Pukkala E, Sankila R, Aaltonen LA, Mecklin JP, et al. Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. Gastroenterology. 2005;129:415-421.
30. Scott RJ, McPhillips M, Meldrum CJ, Fitzgerald PE, Adams K, Spigelman AD, et al. Hereditary nonpolyposis colorectal cancer in 95 families: differences and similarities between mutation-positive and mutation-negative kindreds. Am J Hum Genet. 2001;68:118-127.
31. Vasen HF, Taal BG, Nagengast FM, Griffioen G, Menko FH, Kleibeuker JH, et al. Hereditary nonpolyposis colorectal cancer: results of long-term surveillance in 50 families. Eur J Cancer. 1995;31A:1145-1148.
32. Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol. 2008;26:5783-5788.
33. Ramsoekh D, van Leerdam ME, Wagner A, Kuipers EJ, Steyerberg EW. Mutation prediction models in Lynch syndrome: evaluation in a clinical genetic setting. J Med Genet. 2009;46:745-751.
34. National Comprehensive Cancer Network. Colorectal Cancer Screening. Fort Washington, PA: National Comprehensive Cancer Network; 2011.
35. Söreide K, Janssen EA, Söiland H, Körner H, Baak JP. Microsatellite instability in colorectal cancer. Br J Surg. 2006;93:395-406.
36. Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology. 1999; 116:1453-1456.
37. Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Rüschoff J, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96: 261-268.
38. Balmaňa J, Balaguer F, Castellví-Bel S, Steyerberg EW, Andreu M, Llor X, et al; Gastrointestinal Oncology Group of the Spanish Gastroenterological Association. Comparison of predictive models, clinical criteria and molecular tumour screening for the identification of patients with Lynch syndrome in a population-based cohort of colorectal cancer patients. J Med Genet. 2008;45: 557-563.
39. Kastrinos F, Steyerberg EW, Mercado R, Balmaňa J, Holter S, Gallinger S, et al. The PREMM(1,2,6) model predicts risk of MLH1, MSH2, and MSH6 germline mutations based on cancer history. Gastroenterology. 2011;140:73-81.
40. Green RC, Parfrey PS, Woods MO, Younghusband HB. Prediction of Lynch syndrome in consecutive patients with colorectal cancer. J Natl Cancer Inst. 2009;101:331-340.
41. U.S. Preventive Services Task Force. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008;149:627-637.
42. Winawer SJ, Zauber AG, O'Brien MJ, Ho MN, Gottlieb L, Sternberg SS, et al. Randomized comparison of surveillance intervals after colonoscopic removal of newly diagnosed adenomatous polyps. The National Polyp Study Workgroup. N Engl J Med. 1993;328:901-906.
43. Selby JV, Friedman GD, Quesenberry CP Jr, Weiss NS. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med. 1992;326:653-657.
44. Ladabaum U, Song K. Projected national impact of colorectal cancer screening on clinical and economic outcomes and health services demand. Gastroenter-ology. 2005;129:1151-1162.
45. Pignone M, Saha S, Hoerger T, Mandelblatt J. Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;137:96-104.
46. Lipscomb J, Weinstein MC, Torrance GW. Time preference. In: Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford Univ Pr; 1996:214-235.
47. Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276:1339-1341.
48. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA. 1996; 276:1253-1258.
49. Briggs A, Claxton K, Sculpher M. Making Decision Models Probabilistic. Decision Modelling for Health Economic Evaluation. Cambridge, MA: Oxford Univ Pr; 2006:77-120.
50. Palomaki GE, McClain MR, Melillo S, Hampel HL, Thibodeau SN. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med. 2009;11:42-65.
51. Gaff CL, Clarke AJ, Atkinson P, Sivell S, Elwyn G, Iredale R, et al. Process and outcome in communication of genetic information within families: a systematic review. Eur J Hum Genet. 2007;15:999-1011.
52. Mesters I, Ausems M, Eichhorn S, Vasen H. Informing one's family about genetic testing for hereditary non-polyposis colorectal cancer (HNPCC): a retrospective exploratory study. Fam Cancer. 2005;4:163-167.
53. Peterson SK, Watts BG, Koehly LM, Vernon SW, Baile WF, Kohlmann WK, et al. How families communicate about HNPCC genetic testing: findings from a qualitative study. Am J Med Genet C Semin Med Genet. 2003;119C:78-86.
54. Aktan-Collan K, Haukkala A, Pylvänäinen K, Järvinen HJ, Aaltonen LA, Peltomäki P, et al. Direct contact in inviting high-risk members of hereditary colon cancer families to genetic counselling and DNA testing [Letter]. J Med Genet. 2007;44:732-738.
55. Geary J, Thomas HJ, Mackay J, Dorkins H, Barwell J, Hodgson SV. The management of families affected by hereditary non-polyposis colorectal cancer (HNPCC). Fam Cancer. 2007;6:13-29.
56. Dugan RB, Wiesner GL, Juengst ET, O'Riordan M, Matthews AL, Robin NH. Duty to warn at-risk relatives for genetic disease: genetic counselors' clinical experience. Am J Med Genet C Semin Med Genet. 2003;119C:27-34.
57. Falk MJ, Dugan RB, O'Riordan MA, Matthews AL, Robin NH. Medical geneticists' duty to warn at-risk relatives for genetic disease. Am J Med Genet A. 2003;120A:374-380.
58. Offit K, Groeger E, Turner S, Wadsworth EA, Weiser MA. The "duty to warn" a patient's family members about hereditary disease risks. JAMA. 2004; 292:1469-1473.
59. Vasen HF, Möslein G, Alonso A, Aretz S, Bernstein I, Bertario L, et al. Recommendations to improve identification of hereditary and familial colorectal cancer in Europe. Fam Cancer. 2010;9:109-115.
60. Peres J. To screen or not to screen for Lynch syndrome. J Natl Cancer Inst. 2010;102:1382-1384.
61. Overbeek LI, Ligtenberg MJ, Willems RW, Hermens RP, Blokx WA, Dubois SV, et al. Interpretation of immunohistochemistry for mismatch repair proteins is only reliable in a specialized setting. Am J Surg Pathol. 2008;32:1246-1251.
62. Zhang L. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part 2. The utility of microsatellite instability testing. J Mol Diagn. 2008;10:301-307.
63. Dinh TA, Rosner BI, Atwood JC, Boland CR, Syngal S, Vasen HF, et al. Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population. Cancer Prev Res (Phila). 2011;4:9-22.
64. Hampel H. Point: justification for Lynch syndrome screening among all patients with newly diagnosed colorectal cancer. J Natl Compr Canc Netw. 2010; 8:597-601.
65. Hall MJ. Counterpoint: implementing population genetic screening for Lynch Syndrome among newly diagnosed colorectal cancer patients-will the ends justify the means? J Natl Compr Canc Netw. 2010;8:606-611.
66. Fishel R, Lescoe MK, Rao MR, Copeland NG, Jenkins NA, Garber J, et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell. 1993;75:1027-1038.
67. Cederquist K, Golovleva I, Emanuelsson M, Stenling R, Grönberg H. A population based cohort study of patients with multiple colon and endometrial cancer: correlation of microsatellite instability (MSI) status, age at diagnosis and cancer risk. Int J Cancer. 2001;91:486-491.
68. Gritz ER, Peterson SK, Vernon SW, Marani SK, Baile WF, Watts BG, et al. Psychological impact of genetic testing for hereditary nonpolyposis colorectal cancer. J Clin Oncol. 2005;23:1902-1910.
69. Murakami Y, Okamura H, Sugano K, Yoshida T, Kazuma K, Akechi T, et al. Psychologic distress after disclosure of genetic test results regarding hereditary nonpolyposis colorectal carcinoma. Cancer. 2004;101:395-403.
70. Ersig AL, Hadley DW, Koehly LM. Colon cancer screening practices and disclosure after receipt of positive or inconclusive genetic test results for hereditary nonpolyposis colorectal cancer. Cancer. 2009;115:4071-4079.
71. Hadley DW, Jenkins JF, Steinberg SM, Liewehr D, Moller S, Martin JC, et al. Perceptions of cancer risks and predictors of colon and endometrial cancer screening in women undergoing genetic testing for Lynch syndrome. J Clin Oncol. 2008;26:948-954.
72. Collins VR, Meiser B, Ukoumunne OC, Gaff C, St John DJ, Halliday JL. The impact of predictive genetic testing for hereditary nonpolyposis colorectal cancer: three years after testing. Genet Med. 2007;9:290-297.
73. Centers for Disease Control and Prevention (CDC). Vital signs: colorectal cancer screening among adults aged 50-75 years-United States, 2008. MMWR Morb Mortal Wkly Rep. 2010;59:808-812.
74. Rabeneck L, Paszat LF, Hilsden RJ, Saskin R, Leddin D, Grunfeld E, et al. Bleeding and perforation after outpatient colonoscopy and their risk factors in usual clinical practice. Gastroenterology. 2008;135:1899-1906, 1906.e1.
75. Whitlock EP, Lin JS, Liles E, Beil TL, Fu R. Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2008;149:638-658.
76. Anderson ML, Pasha TM, Leighton JA. Endoscopic perforation of the colon: lessons from a 10-year study. Am J Gastroenterol. 2000;95:3418-3422.
77. Arora G, Mannalithara A, Singh G, Gerson LB, Triadafilopoulos G. Risk of perforation from a colonoscopy in adults: a large population-based study. Gas-trointest Endosc. 2009;69:654-664.
78. Gatto NM, Frucht H, Sundararajan V, Jacobson JS, Grann VR, Neugut AI. Risk of perforation after colonoscopy and sigmoidoscopy: a population-based study. J Natl Cancer Inst. 2003;95:230-236.
79. Braga M, Vignali A, Gianotti L, Zuliani W, Radaelli G, Gruarin P, et al. Laparoscopic versus open colorectal surgery: a randomized trial on short-term outcome. Ann Surg. 2002;236:759-766.
80. Leung KL, Kwok SP, Lam SC, Lee JF, Yiu RY, Ng SS, et al. Laparoscopic resection of rectosigmoid carcinoma: prospective randomised trial. Lancet. 2004; 363:1187-1192.
81. Milsom JW, Böhm B, Hammerhofer KA, Fazio V, Steiger E, Elson P. A prospective, randomized trial comparing laparoscopic versus conventional techniques in colorectal cancer surgery: a preliminary report. J Am Coll Surg. 1998; 187:46-54.
82. Schwenk W, Haase O, Neudecker J, Müller JM. Short term benefits for laparoscopic colorectal resection. Cochrane Database Syst Rev. 2005:CD003145.
83. Yang K, Allen B, Conrad P, Powell CB, Terdiman J, Chen LM. Awareness of gynecologic surveillance in women from hereditary non-polyposis colorectal cancer families. Fam Cancer. 2006;5:405-409.
84. Renkonen-Sinisalo L, Bützow R, Leminen A, Lehtovirta P, Mecklin JP, Järvinen HJ. Surveillance for endometrial cancer in hereditary nonpolyposis colo-rectal cancer syndrome. Int J Cancer. 2007;120:821-824.
85. Gerritzen LH, Hoogerbrugge N, Oei AL, Nagengast FM, van Ham MA, Massuger LF, et al. Improvement of endometrial biopsy over transvaginal ultrasound alone for endometrial surveillance in women with Lynch syndrome. Fam Cancer. 2009;8:391-7.
86. Horner MJ, Ries LA, Krapcho M, Neyman N, Aminou R, Howlader N, et al, eds. SEER Cancer Statistics Review, 1975-2006. Based on November 2008 SEER data submission. Bethesda, MD: National Cancer Institute; 2009. Accessed at http://seer.cancer.gov/csr/1975_2006/ on 17 May 2011.
87. Gryfe R, Kim H, Hsieh ET, Aronson MD, Holowaty EJ, Bull SB, et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med. 2000;342:69-77.
88. National Center for Health Statistics, Centers for Disease Control and Prevention. Vital Statistics of the United States. Preprint of Vol 2, Mortality, part A, section 6. Hyattsville, MD: National Center for Health Statistics; 2003.
89. Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroen-terology. 2010;138:2073-2087.e3.
90. Centers for Medicare & Medicaid Services. Acute Inpatient Prospective Payment System. Baltimore: Centers for Medicare & Medicaid Services; 2010. Accessed at www.cms.gov/ AcuteInpatientPPS on 17 May 2010.
91. Centers for Medicare & Medicaid Services. Physician Fee Schedule. Baltimore: Centers for Medicare & Medicaid Services; 2010. Accessed at www.cms.gov/PhysicianFeeSched/ on 17 May 2010.
92. Havrilesky LJ, Maxwell GL, Myers ER. Cost-effectiveness analysis of annual screening strategies for endometrial cancer. Am J Obstet Gynecol. 2009;200: 640.e1-8.
93. Zauber AG, Lansdorp-Vogelaar I, Wilschut J, Knudsen AB, van Ballegooi-jen M, Kuntz KM. Technology Assessment: Cost-Effectiveness of DNA Stool Testing to Screen for Colorectal Cancer. Report to AHRQ and CMS from the Cancer Intervention and Surveillance Modeling Network (CISNET) for MIS-CAN and SimCRC Models. Rockville, MD: Agency for Healthcare Research and Quality; 2007.
94. Havrilesky LJ, Sanders GD, Kulasingam S, Myers ER. Reducing ovarian cancer mortality through screening: Is it possible, and can we afford it? Gynecol Oncol. 2008;111:179-187.
95. U.S. Department of Labor, Bureau of Labor Statistics. Consumer Price Index. Washington, DC: U.S. Bureau of Labor Statistics; 2010. Accessed at www.bls.gov/cpi/home.htm on 19 May 2011.
96. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med. 2009;11:35-41.
97. Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med. 2003;348:919-32.
98. National Library of Medicine. Genetics Home Reference. Vol. 2011; 2011.
99. Chen S, Wang W, Lee S, Nafa K, Lee J, Romans K, et al; Colon Cancer Family Registry. Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA. 2006;296:1479-87.
100. Martin SA, Lord CJ, Ashworth A. Therapeutic targeting of the DNA mismatch repair pathway. Clin Cancer Res. 2010;16:5107-5013.
101. Shia J. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part 1. The utility of immunohistochemistry. J Mol Diagn. 2008;10:293-300.
102. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, et al; ASCO. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006;24:5313-5327.
103. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, et al. A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998;58:5248-5257.